Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Reproductive Biology and Endocrinology
Published in: Reproductive Biology and Endocrinology 1/2021

Open Access 01-12-2021 | Infertility | Research

Expression of tissue factor and tissue factor pathway inhibitors during ovulation in rats: a relevance to the ovarian hyperstimulation syndrome

Authors: You Jee Jang, Hee Kyung Kim, Bum Chae Choi, Sang Jin Song, Jae Il Park, Sang Young Chun, Moon Kyoung Cho

Published in: Reproductive Biology and Endocrinology | Issue 1/2021

Login to get access

Abstract

Background

Blood coagulation has been associated with ovulation and female infertility. In this study, the expression of the tissue factor system was examined during ovulation in immature rats; the correlation between tissue factor and ovarian hyperstimulation syndrome (OHSS) was evaluated both in rats and human follicular fluids.

Methods

Ovaries were obtained at various times after human chorionic gonadotropin (hCG) injection to investigate the expression of tissue factor system. Expression levels of ovarian tissue factor, tissue factor pathway inhibitor (Tfpi)-1 and Tfpi-2 genes and proteins were determined by real-time quantitative polymerase chain reaction (qPCR), and Western blot and immunofluorescence analyses, respectively. Expression levels of tissue factor system were also investigated in ovaries of OHSS-induced rats and in follicular fluid of infertile women.

Results

The expression of tissue factor in the preovulatory follicles was stimulated by hCG, reaching a maximum at 6 h. Tissue factor was expressed in the oocytes and the preovulatory follicles. Tfpi-2 mRNA levels were mainly increased by hCG in the granulosa cells whereas the mRNA levels of Tfpi-1 were decreased by hCG. Human CG-stimulated tissue factor expression was inhibited by the progesterone receptor antagonist. The increase in Tfpi-2 expression by hCG was decreased by the proliferator-activated receptor γ (PPARγ) antagonist. Decreased expression of the tissue factor was detected in OHSS-induced rats. Interestingly, the tissue factor concentrations in the follicular fluids of women undergoing in vitro fertilization were correlated with pregnancy but not with OHSS.

Conclusions

Collectively, the results indicate that tissue factor and Tfpi-2 expression is stimulated during the ovulatory process in rats; moreover, a correlation exists between the levels of tissue factor and OHSS in rats but not in humans.
Appendix
Available only for authorised users
Literature
1.
2.
Oakley OR, Kim H, El-Amouri I, Lin PC, Cho J, Bani-Ahmad M, Ko C. Periovulatory leukocyte infiltration in the rat ovary. Endocrinology. 2010;151(9):4551–9.PubMedPubMedCentralCrossRef
3.
Park JI, Jeon HJ, Jung NK, Jang YJ, Kim JS, Seo YW, Jeong M, Chae HZ, Chun SY. Periovulatory expression of hydrogen peroxide-induced sulfiredoxin and peroxiredoxin 2 in the rat ovary. Gonadotropin regulation and potential modification. Endocrinology. 2012;153(11):5512–21.PubMedCrossRef
4.
Parrott JA, Whaley PD, Skinner MK. Extrahepatic expression of fibrinogen by granulosa cells. Potential role in ovulation. Endocrinology. 1993;133(4):1645–9.PubMedCrossRef
5.
Cheng Y, Kawamura K, Deguchi M, Takae S, Mulders SM, Hsueh AJ. Intraovarian thrombin and activated protein C signaling system regulates steroidogenesis during the periovulatory period. Mol Endocrinol. 2012;26(2):331–40.PubMedCrossRef
6.
Roach LE, Petrik JJ, Plante L, LaMarre J, Gentry PA. Thrombin generation and presence of thrombin receptor in ovarian follicles. Biol Reprod. 2002;66(5):1350–8.PubMedCrossRef
7.
Hirota Y, Tachibana O, Uchiyama N, Hayashi Y, Nakada M, Kita D, Watanabe T, Higashi R, Hamada J. Gonadotropin-releasing hormone (GnRH) and its receptor in human meningiomas. Clin Neurol Neurosurg. 2009;111(2):127–33.PubMedCrossRef
8.
Gentry PA, Plante L, Schroeder MO, LaMarre J, Young JE, Dodds WG. Human ovarian follicular fluid has functional systems for the generation and modulation of thrombin. Fertil Steril. 2000;73(4):848–54.PubMedCrossRef
9.
Kim YS, Kim MS, Lee SH, Choi BC, Lim JM, Cha KY, Baek KH. Proteomic analysis of recurrent spontaneous abortion: identification of an inadequately expressed set of proteins in human follicular fluid. Proteomics. 2006;6(11):3445–54.PubMedCrossRef
10.
Cimmino G, Cirillo P. Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis. Cardiovasc Diagn Ther. 2018;8(5):581–93.PubMedPubMedCentralCrossRef
11.
Price GC, Thompson SA, Kam PC. Tissue factor and tissue factor pathway inhibitor. Anaesthesia. 2004;59(2004):483–92.PubMedCrossRef
12.
Bungay SD, Gentry PA, Gentry RD. Modelling thrombin generation in human ovarian follicular fluid. Bull Math Biol. 2006;68(8):2283–302.PubMedCrossRef
13.
Puttabyatappa M, Al-Alem LF, Zakerkish F, Rosewell KL, Brannstrom M, Curry TE Jr. Induction of tissue factor pathway inhibitor 2 by hCG regulates Periovulatory gene expression and plasmin activity. Endocrinology. 2017;158(1):109–20.PubMedCrossRef
14.
Kwak-Kim J, Yang KM, Gilman-Sachs A. Recurrent pregnancy loss: a disease of inflammation and coagulation. J Obstet Gynaecol Res. 2009;35(4):609–22.PubMedCrossRef
15.
Ebner T, Moser M, Shebl O, Sommergruber M, Yaman C, Tews G. Blood clots in the cumulus-oocyte complex predict poor oocyte quality and post-fertilization development. Reprod BioMed Online. 2008;16(6):801–7.PubMedCrossRef
16.
17.
Carvalho LML, Ferreira CN, Candido AL, Reis FM, Soter MO, Sales MF, Silva IFO, Nunes FFC, Gomes KB. Metformin reduces total microparticles and microparticles-expressing tissue factor in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2017;296(4):617–21.PubMedCrossRef
18.
Gonzalez F, Kirwan JP, Rote NS, Minium J. Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clin Appl Thromb Hemost. 2013;19(3):66–72.PubMedCrossRef
19.
Thyzel E, Siegling S, Tinneberg HR, Gotting C, Kleesiek K. Age dependent assessment of TFPI levels in follicular fluid of women undergoing IVF. Clin Chim Acta. 2005;361(1–2):176–81.PubMedCrossRef
20.
Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS). A review. Hum Reprod Update. 2002;8(6):559–77.PubMedCrossRef
21.
Ishikawa K, Ohba T, Tanaka N, Iqbal M, Okamura Y, Okamura H. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats. Endocr J. 2003;50(5):515–25.PubMedCrossRef
22.
Ohba T, Ujioka T, Ishikawa K, Tanaka N, Okamura H. Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication. Mol Cell Endocrinol. 2003;202(1–2):47–52.PubMedCrossRef
23.
Gao F, Vasquez SX, Su F, Roberts S, Shah N, Grijalva V, Imaizumi S, Chattopadhyay A, Ganapathy E, Meriwether D, Johnston B, Anantharamaiah GM, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb). 2011;3(4):479–89.CrossRef
24.
Shen BQ, Lee DY, Cortopassi KM, Damico LA, Zioncheck TF. Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. J Biol Chem. 2001;276(7):5281–6.PubMedCrossRef
25.
Balasch J, Reverter JC, Fabregues F, Tassies D, Ordinas A, Vanrell JA. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil Steril. 1996;66(4):608–13.PubMedCrossRef
26.
Rogolino A, Coccia ME, Fedi S, Gori AM, Cellai AP, Scarselli GF, Prisco D, Abbate R. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood Coagul Fibrinolysis. 2003;14(3):277–82.PubMed
27.
Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome--views and ideas. Hum Reprod. 1997;12(6):1129–37.PubMedCrossRef
28.
Robker RL, Hennebold JD, Russell DL. Coordination of ovulation and oocyte maturation: a good egg at the right time. Endocrinology. 2018;159(9):3209–18.PubMedPubMedCentralCrossRef
29.
Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 1995;9(18):2266–78.PubMedCrossRef
30.
Parr EL. Absence of neutral proteinase activity in rat ovarian follicle walls at ovulation. Biol Reprod. 1974;11(5):509–12.PubMedCrossRef
31.
32.
Lu E, Li C, Wang J, Zhang C. Inflammation and angiogenesis in the corpus luteum. J Obstet Gynaecol Res. 2019;45(10):1967–74.PubMedCrossRef
33.
Berisha B, Schams D, Rodler D, Pfaffl MW. Angiogenesis in the ovary - the Most important regulatory event for follicle and corpus luteum development and function in cow - an overview. Anat Histol Embryol. 2016;45(2):124–30.PubMedCrossRef
34.
35.
Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94(3):1320–7.PubMedPubMedCentralCrossRef
36.
Miura R, Haneda S, Matsui M. Ovulation of the preovulatory follicle originating from the first-wave dominant follicle leads to formation of an active corpus luteum. J Reprod Dev. 2015;61(4):317–23.PubMedPubMedCentralCrossRef
37.
Kwik M, Maxwell E. Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol. 2016;28(4):236–41.PubMedCrossRef
38.
Naredi N, Talwar P, Sandeep K. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: current status. Med J Armed Forces India. 2014;70(1):58–63.PubMedCrossRef
39.
Shimada H, Kasakura S, Shiotani M, Nakamura K, Ikeuchi M, Hoshino T, Komatsu T, Ihara Y, Sohma M, Maeda Y, Matsuura R, Nakamura S, Hine C, Ohkura N, Kato H. Hypocoagulable state of human preovulatory ovarian follicular fluid: role of sulfated proteoglycan and tissue factor pathway inhibitor in the fluid. Biol Reprod. 2001;64(6):1739–45.PubMedCrossRef
40.
Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry. 1996;35(1):266–72.PubMedCrossRef
41.
Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol. 1998;18(1):40–6.PubMedCrossRef
42.
Chand HS, Foster DC, Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost. 2005;94(6):1122–30.PubMedCrossRef
43.
Rao CN, Cook B, Liu Y, Chilukuri K, Stack MS, Foster DC, Kisiel W, Woodley DT. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer. 1998;76(5):749–56.PubMedCrossRef
44.
Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, Schonbeck U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001;107(9):1117–26.PubMedPubMedCentralCrossRef
45.
Komar CM. Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol. 2005;3:41.PubMedPubMedCentralCrossRef
Metadata
Title
Expression of tissue factor and tissue factor pathway inhibitors during ovulation in rats: a relevance to the ovarian hyperstimulation syndrome
Authors
You Jee Jang
Hee Kyung Kim
Bum Chae Choi
Sang Jin Song
Jae Il Park
Sang Young Chun
Moon Kyoung Cho
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Reproductive Biology and Endocrinology / Issue 1/2021
Electronic ISSN: 1477-7827
DOI
https://doi.org/10.1186/s12958-021-00708-1

Other articles of this Issue 1/2021

Reproductive Biology and Endocrinology 1/2021 Go to the issue

Research

Individualized embryo selection strategy developed by stacking machine learning model for better in vitro fertilization outcomes: an application study

Research

Impact of infertility duration on female sexual health

Research

Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis

Research

Maternal and infant outcomes during the COVID-19 pandemic: a retrospective study in Guangzhou, China

Research

microRNA-194 is increased in polycystic ovary syndrome granulosa cell and induce KGN cells apoptosis by direct targeting heparin-binding EGF-like growth factor

Review

What is the impact of granulocyte colony-stimulating factor (G-CSF) in subcutaneous injection or intrauterine infusion and during both the fresh and frozen embryo transfer cycles on recurrent implantation failure: a systematic review and meta-analysis?